Angiodynamics, Inc. · NASDAQ:ANGO
Angiodynamics — Merger or Acquisition (January 2012)
12 slides from Angiodynamics's merger presentation, Jan 31, 2012
Slide 1: Acquisition of Navilyst Medical
Exhibit 99.1 Acquisition of Navilyst Medical Investor Conference Call | January 31, 2012
Slide 2: Forward-Looking Statements
Forward-Looking Statements Safe Harbor This document includes “forward-looking statements” intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Investors can identify these statements by the fact that they do not relate strictly
Slide 3: Overview of Navilyst
Overview of Navilyst Navilyst Medical • Navilyst Medical is a global medical CY 2011 Revenue: $149M device company focused on vascular access, interventional radiology and interventional cardiology markets • Acquired by Avista Capital Partners from Boston Scientific in February 2008 • $149 million o
Slide 4: Navilyst Adds to AngioDynamics …
Navilyst Adds to AngioDynamics … 4
Slide 5: Scale: Broad Portfolio of Respected Brands Enhances Competitiveness
Scale Broad Portfolio of Respected Brands Enhances Competitiveness Full Line of Vascular Access Products PICCs and Ports Market Presence Others ANGO BEFORE Navilyst Bard TRANSACTION Others COMBINED PRO Bard FORMA 5
Slide 6: Scale: Fluid Management Leadership Provides Entrée into the Cath Lab
Scale Fluid Management Leadership Provides Entrée into the Cath Lab NAMIC® Fluid Management Navilyst Fluid Management Business Components • NAMIC® has been the “gold standard” in fluid management for the past 40 years • Broadest line of products available, with > 5,000 SKUs • Loyal customer base due
Slide 7: Technology: PASV Valve
Technology Compelling Products and Enabling Platforms - PASV® Valve PASV® - A Sustainable Competitive Advantage • Patent protected: Pressure Activated Safety Valve - Proximal 3-way valve - Direction specific and pressure activated • Clinically proven benefits for both patients and hospitals - Reduce
Slide 8: Technology: BioFlo
Technology Compelling Products and Enabling Platforms – BioFlo® BioFlo® Platform - High Upside Potential • Venous thrombosis continues to be of concern - Thrombosis rates are as high as 23% - DVT complications are increasing - Current offerings have significant limitations • BioFlo® technology is …
Slide 9: Operational Excellence
Operational Excellence Forging a “Continuous Improvement” Culture • Sourcing (economies of scale) AngioDynamics • Catheter Assembly to Navilyst • Electromechanical Assembly • Extrusion • Sourcing (economies of scale) · Custom Kitting Navilyst to • Injection Molding · Lean Practices AngioDynamics • R
Slide 10: Improved Financial Performance
Improved Financial Performance Scale, Technology and Operational Excellence Driving Shareholder Value Financial Highlights Earnings Per Share Accretive to FY13 Non-GAAP EPS* by at least $0.08/share Net Sales ~$360M Net Sales in FY13 EBITDA $60M Adjusted EBITDA* in FY13 $5-7M net cost savings in firs
Slide 11: Transaction Overview
Transaction Overview Key Terms Summary Points Transaction Value $372M* Consideration to Navilyst 63% cash ($237M) Shareholders 37% stock ($135M*) 9.5M ANGO shares AngioDynamics’ existing shareholders: ~73% Avista ownership: ~27% Ownership Structure • Subject to transfer and voting restrictions • 2 a
Slide 12: AngioDynamics & Navilyst Medical
AngioDynamics & Navilyst Medical Creating a World-Class Platform for Growth Improved Financial Performance 12